-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

651A.O2.6 651. Multiple Myeloma and Plasma Cell Dyscrasias Basic and Translational: Genomic Markers of Disease Progression and Therapeutic Response

Symposia: Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational Program: Oral and Poster Abstracts
Type: Oral
Hematology Disease Topics & Pathways:
Research, Biological therapies, Fundamental Science, adult, Translational Research, assays, genomics, bioinformatics, Chimeric Antigen Receptor (CAR)-T Cell Therapies, Plasma Cell Disorders, Diseases, Gene Therapy, Therapies, Lymphoid Malignancies, computational biology, Biological Processes, Technology and Procedures, Study Population, Human, pathogenesis, omics technologies
Sunday, December 11, 2022: 4:30 PM-6:00 PM
New Orleans Theater AB (Ernest N. Morial Convention Center)
Moderators:
Raphael E Szalat, MD, PhD, Boston University School of Medicine and Niccolo Bolli, MD, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico & University of Milan
Disclosures:
No relevant conflicts of interest to declare.
4:30 PM

Eugenio Morelli, MD1, Annamaria Gulla, MD2, Na Liu3*, Domenico Maisano, PhD4*, Anil Aktas-Samur, PhD5*, Nicola Amodio, PhD6*, Caroline Ribeiro, PhD7*, Leon Wert-Lamas, PhD3*, Jonathan Henninger8*, Srikanth Talluri, PhD9*, Megan Johnstone10*, Doriana Gramegna1*, Delaney Vinaixa11*, Antonino Neri, MD12, Dharminder Chauhan, PhD13*, Teru Hideshima, MD, PhD1, Masood A. Shammas, PhD14*, Pierfrancesco Tassone, MD15*, Sergei Gryaznov16*, Richard A. Young, PhD17*, Kenneth C. Anderson, MD9, Carl D. Novina, MD, PhD9, Massimo Loda, MD18*, Mariateresa Fulciniti, PhD9, Mehmet K. Samur, PhD9 and Nikhil C Munshi, MD, PhD19

1Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston
2Medical Oncology, Dana Farber Cancer Institute, Boston, MA
3Dana-Farber Cancer Institute, Boston
4Dana Farber Cancer Institute, Boston, MA
5Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA
6Department of Experimental and Clinical Medicine, University Magna Graecia of Catanzaro, Catanzaro, Italy
7Cornell University, new york
8Whitehead Institute of Biomedical Research, Cambridge, MA
9Dana-Farber Cancer Institute, Boston, MA
10Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
11Medical Oncology, Dana-Farber Cancer Institute, Boston
12BMT Center - Hematology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, MI, Italy
13Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
14The Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston
15Magna Graecia University, Catanzaro, Italy
16Maia Biotechnology Inc., CHICAGO, IL
17Whitehead Institute For Biomedical Research/ MIT, Cambridge, MA
18Weill Cornell Medical College, New York, NY
19Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Boston, MA

4:45 PM

Monika Chojnacka, BS1, Benjamin Diamond2*, Bachisio Ziccheddu, PhD3*, Even Rustad4*, Eileen Boyle5*, Kylee H Maclachlan, MBBCh, PhD6, Patrick Blaney7*, Saad Usmani, MD7, Gareth J. Morgan, MD5, Ola Landgren, MD2 and Francesco Maura, MD8

1Myeloma Service, Sylvester Comprehensive Cancer Center, University of Miami, Miami
2Myeloma Division, University of Miami, Sylvester Comprehensive Cancer Center, Miami
3Myeloma Service, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL
4Institute for Cancer Research, Oslo University Hospital, Oslo, Norway
5Myeloma Research Program, NYU Langone, Perlmutter Cancer Center, New York
6Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
7Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York
8Myeloma Program, Department of Medicine, University of Miami, Sylvester Comprehensive Cancer Center, PALMETTO BAY, FL

5:00 PM

Mehmet K. Samur, PhD1, Jill Corre2*, Luka Pavageau3*, Laure Buisson4*, Nikhil C Munshi, MD, PhD5 and Herve Avet-Loiseau, MD, PhD6*

1Dana-Farber Cancer Institute, Boston, MA
2Toulouse, and CRCT, Toulouse, France, Toulouse, France
3Iuct-Oncopole, Toulouse, FRA
4Iuct-Oncopole, TOULOUSE, FRA
5Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Boston, MA
6Unit for Genomics in Myeloma, Institut Universitaire du Cancer de Toulouse-Oncopole, University Hospital, Toulouse, France

5:15 PM

Hitomi Hosoya, MD, PhD1, Mia Carleton2*, Kailee L Tanaka2*, Brian Sworder, MD, PhD3, Vanna Hovanky4*, George E Duran, BA2*, Tian Y. Zhang5, Michael S. Khodadoust, MD PhD2, David B. Miklos, MD, PhD4, Sally Arai, MD6, David Iberri, MD2, Michaela Liedtke, MD2, Surbhi Sidana, MD7 and David M. Kurtz, MD, PhD1

1Divisions of Oncology and Hematology, Department of Medicine, Stanford University School of Medicine, Stanford, CA
2Department of Medicine, Divisions of Oncology and Hematology, Stanford University, Stanford, CA
3Division of Oncology, Department of Medicine, Stanford University School of Medicine, Stanford, CA
4Department of Medicine, Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford University, Stanford, CA
5Division of Hematology, Department of Medicine, Stanford University Medical Center, Stanford, CA
6Division of Blood and Marrow Transplantation and Cellular Therapy, Department of Medicine, Stanford University Medical Center, Stanford, CA
7Division of Blood and Marrow Transplantation and Cellular Therapy, Department of Medicine, Stanford University School of Medicine, Stanford, CA

5:30 PM

Maria Luisa Guerrera, MD1*, Xia Liu, MD1*, Eugenio Morelli, MD2, Kris Richardson, PhD1*, Nickolas Tsakmaklis1*, Amanda Kofides1*, Manit Munshi, MS1*, Shirong Liu, MD PhD1*, Guang Yang, PhD1, Christopher J Patterson, MS, MPH1*, Jorge J. Castillo, MD1, Shayna Sarosiek, MD1, Catherine A. Flynn, NP1*, Kirsten Meid, MPH1*, Joshua Gustine, MPH1*, Andrew R. Branagan, MD3, Alessandra Trojani, PhD4*, Alessandra Tedeschi4*, Roberto Cairoli4*, Tomasz Sewastianik, PhD5*, Ruben D. Carrasco, MD, PhD5*, Kenneth C. Anderson, MD2, Nikhil C Munshi, MD, PhD2, Steven P Treon, MD, PhD1 and Zachary R Hunter, PhD1

1Bing Center for Waldenstrom's macroglobulinemia, Dana-Farber Cancer Institute, Boston, MA
2Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Boston, MA
3Center for Multiple Myeloma, Massachusetts General Hospital Cancer Center, Boston, MA
4Department of Hematology, ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy
5Department of Pathology, Dana-Farber Cancer Institute, Boston, MA

5:45 PM

Francesco Maura, MD1, David Coffey, MD1, Esteban Braggio, PhD2, Caleb K Stein, PhD3*, Meaghen E Sharik, BS3*, Megan T Du, B.S.3*, Bachisio Ziccheddu, PhD1*, Gareth J. Morgan, MD4, Ola Landgren, MD5, P. Leif Bergsagel, MD6 and Marta Chesi, PhD6

1Myeloma Division, University of Miami, Sylvester Comprehensive Cancer Center, Miami
2Division of Hematology and Medical Oncology, Mayo Clinic, Scottsdale, AZ
3Division of Hematology and Medical Oncology, Mayo Clinic, Scottsdale
4NYU Langone, Perlmutter Cancer Center, New York
5Myeloma Service, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL
6Division of Hematology and Oncology, Mayo Clinic, Scottsdale, AZ

*signifies non-member of ASH